Related Experiment Video
Updated: May 13, 2025
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
MAD2L1-mediated NANOG nuclear translocation: A critical factor in lung cancer chemoresistance
Hongye Zhao1, Yongcun Liu2, Longyu Zhu3
1The Department of Dermatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Abstract:
This study investigates the function of Mitotic Arrest Deficient 2 Like 1 (MAD2L1) and its role in facilitating NANOG nuclear localization, contributing to chemoresistance in lung cancer. Using both in vivo and in vitro models, we examined MAD2L1 expression in Carboplatin-resistant lung cancer cell lines. The study utilized gene knockdown and overexpression techniques to assess MAD2L1's role in chemoresistance and cell stemness, alongside co-expression analysis and fluorescence staining and CO-IP to explore MAD2L1 and NANOG interactions. Results showed a marked increase in MAD2L1 expression in resistant lung cancer cells, correlating with enhanced cell stemness. MAD2L1 knockdown heightened sensitivity to Carboplatin and reduced NANOG expression, while MAD2L1 overexpression led to increased resistance and stemness. Mechanistically, MAD2L1 facilitated NANOG's nuclear localization, with their co-expression linked to increased cell resistance and metastasis in vivo. These findings suggest that MAD2L1 enhances chemoresistance by promoting NANOG localization, offering insights into potential therapeutic targets for overcoming lung cancer chemoresistance.
Insights
Mitotic Arrest Deficient 2 Like 1 (MAD2L1) promotes lung cancer chemoresistance by enabling NANOG nuclear localization. Reducing MAD2L1 enhances drug sensitivity, offering a potential therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Lung cancer exhibits significant chemoresistance, a major obstacle to effective treatment.
- The role of specific proteins like Mitotic Arrest Deficient 2 Like 1 (MAD2L1) in chemoresistance is not fully understood.
- NANOG, a stem cell factor, is implicated in cancer progression and resistance.
Purpose of the Study:
- To investigate the function of MAD2L1 in lung cancer chemoresistance.
- To elucidate the mechanism by which MAD2L1 influences NANOG nuclear localization.
- To assess the therapeutic potential of targeting MAD2L1 in Carboplatin-resistant lung cancer.
Main Methods:
- In vivo and in vitro models of Carboplatin-resistant lung cancer.
- Gene knockdown and overexpression of MAD2L1.
- Co-expression analysis, fluorescence staining, and co-immunoprecipitation (CO-IP) to study protein interactions.
- Assessment of cell stemness and drug sensitivity.
Main Results:
- MAD2L1 expression is significantly upregulated in Carboplatin-resistant lung cancer cells.
- MAD2L1 knockdown increased sensitivity to Carboplatin and decreased NANOG expression.
- MAD2L1 overexpression enhanced chemoresistance and cell stemness.
- MAD2L1 facilitates NANOG nuclear localization, promoting chemoresistance and metastasis.
Conclusions:
- MAD2L1 plays a critical role in promoting lung cancer chemoresistance by enhancing NANOG nuclear localization.
- Targeting MAD2L1 may represent a viable strategy to overcome chemoresistance in lung cancer.
- Further research into the MAD2L1-NANOG axis could yield novel therapeutic interventions.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
02:56Treatment Resistant Cancers
02:23Abnormal Proliferation